Lead sponsor
Dongguan HEC Biopharmaceutical R&D Co., Ltd.
3 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
3
Trials led
0
Active
462
Total enrollment
4
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
2
Phase 2
1
Trials by status
Completed
3
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes MellitusHbA1c 7.5-10.5%Ph 2Completed234
A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM SubjectsBMI ≤28Ph 1Completed164